Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?

Rupert W L Leong^{1

2}, Nadeem O Kaakoush³, Yunki Y Yau^{2

4}, Valerie C Wasinger⁴

Affiliations

¹ Faculty of Medicine, South Western Clinical School, UNSW, Sydney, Australia.
² Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia.
³ School of Medical Sciences, UNSW, Sydney, Australia.
⁴ Bioanalytical Mass Spectrometry Facility, UNSW, Sydney, Australia.

Editorial

Rupert W L Leong et al. Aliment Pharmacol Ther. 2019 Apr.

. 2019 Apr;49(8):1086-1087.

doi: 10.1111/apt.15171.

Rupert W L Leong^{1

2}, Nadeem O Kaakoush³, Yunki Y Yau^{2

4}, Valerie C Wasinger⁴

¹ Faculty of Medicine, South Western Clinical School, UNSW, Sydney, Australia.
² Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia.
³ School of Medical Sciences, UNSW, Sydney, Australia.
⁴ Bioanalytical Mass Spectrometry Facility, UNSW, Sydney, Australia.

No abstract available

Comment in

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA. Keshteli AH, et al. Aliment Pharmacol Ther. 2019 Apr;49(8):1088-1089. doi: 10.1111/apt.15200. Aliment Pharmacol Ther. 2019. PMID: 30920043 No abstract available.
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
Bond A, Probert C. Bond A, et al. Aliment Pharmacol Ther. 2019 Apr;49(8):1087-1088. doi: 10.1111/apt.15196. Aliment Pharmacol Ther. 2019. PMID: 30920048 No abstract available.

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA. Keshteli AH, et al. Aliment Pharmacol Ther. 2019 Mar;49(6):723-732. doi: 10.1111/apt.15141. Epub 2019 Jan 31. Aliment Pharmacol Ther. 2019. PMID: 30706502
Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer.
Bond A, Greenwood R, Lewis S, Corfe B, Sarkar S, O'Toole P, Rooney P, Burkitt M, Hold G, Probert C. Bond A, et al. Aliment Pharmacol Ther. 2019 Apr;49(8):1005-1012. doi: 10.1111/apt.15140. Epub 2019 Mar 3. Aliment Pharmacol Ther. 2019. PMID: 30828825 Free PMC article.